Literature DB >> 7798489

Observations suggesting a high incidence of exercise-induced severe mitral regurgitation in patients with mild rheumatic mitral valve disease at rest.

M D Tischler1, R W Battle, M Saha, J Niggel, M M LeWinter.   

Abstract

OBJECTIVES: The aim of this study was to determine the hemodynamic effects of upright bicycle ergometry in symptomatic patients with mild, mixed mitral stenosis and regurgitation.
BACKGROUND: Patients with seemingly mild rheumatic mitral valve disease often complain of exertional dyspnea or fatigue. These symptoms are usually ascribed to flow-dependent increases in the gradient across the stenotic mitral valve. Although catheterization studies in these patients may demonstrate an increase in mitral valve gradient proportional to an increase in cardiac output, this approach does not specifically address the underlying mechanism of any observed increases in mitral gradient or left atrial (i.e., pulmonary capillary wedge) pressure. Exercise echocardiography is uniquely suited to the dynamic assessment of exercise-induced hemodynamic changes.
METHODS: Fourteen symptomatic patients with exertional dyspnea and mild mitral stenosis and regurgitation at rest performed symptom-limited upright bicycle ergometry with quantitative two-dimensional, Doppler and color Doppler echocardiographic analysis.
RESULTS: Average pulmonary artery systolic pressure in the 13 patients with adequate spectral signals of tricuspid regurgitation increased from 36 +/- 5 mm Hg (mean +/- SD) at rest to 63 +/- 14 mm Hg at peak exercise (p < 0.001). The mean transmitral pressure gradient in all patients increased from 4.5 +/- 1.4 mm Hg at rest to 12.7 +/- 2.7 mm Hg at peak exercise (p < 0.001). Five patients developed severe mitral regurgitation during exercise.
CONCLUSIONS: Patients with exertional dyspnea and mild mitral stenosis and regurgitation at rest demonstrate a marked increase in pulmonary artery systolic pressure and mean transmitral pressure gradient during dynamic exercise. In a subset of these patients, marked worsening of mitral regurgitation appears to be the underlying mechanism of this hemodynamic deterioration. Because of the small sample size, this novel observation must be considered preliminary with respect to the true prevalence of exercise-related development of severe mitral regurgitation. If additional studies confirm the importance of this phenomenon, it has important implications for the management of patients with rheumatic mitral valve disease.

Entities:  

Mesh:

Year:  1995        PMID: 7798489     DOI: 10.1016/0735-1097(94)00359-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Therapeutic decision-making for patients with fluctuating mitral regurgitation.

Authors:  Patrizio Lancellotti; Khalil Fattouch; Giovanni La Canna
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 2.  Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.

Authors:  Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

3.  Exercise capacity in adult patients with congenitally corrected transposition of the great arteries.

Authors:  P M Fredriksen; A Chen; G Veldtman; S Hechter; J Therrien; G Webb
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

4.  Tricuspid Valvular Regurgitation.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-02

5.  The use of exercise echocardiography in the evaluation of mitral regurgitation.

Authors:  Kibar Yared; Kaitlyn My-Tu Lam; Judy Hung
Journal:  Curr Cardiol Rev       Date:  2009-11

6.  The role of exercise echocardiography in the management of mitral valve disease.

Authors:  R Jansen; P A M Kracht; M J Cramer; W J Tietge; L A van Herwerden; R J M Klautz; J Kluin; S A J Chamuleau
Journal:  Neth Heart J       Date:  2013-08-20       Impact factor: 2.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.